SRC and colorectal cancer: CD133, a well-established CSC maker [18], interacts with SRC at its C-terminal portion, which, in turn, activates the SRC–FAK complex and the phosphorylation of FAK at Y925, facilitating cell migration in the colorectal cancer cell line SW620 through the CD133/SRC/FAK pathway, which could be blocked by PP2 [82].